N-(5-(5-hydroxypyridin-3-yl)-1H-indazol-3-yl)benzamide

ID: ALA5291397

Max Phase: Preclinical

Molecular Formula: C19H14N4O2

Molecular Weight: 330.35

Names and Identifiers

Canonical SMILES:  O=C(Nc1n[nH]c2ccc(-c3cncc(O)c3)cc12)c1ccccc1

Standard InChI:  InChI=1S/C19H14N4O2/c24-15-8-14(10-20-11-15)13-6-7-17-16(9-13)18(23-22-17)21-19(25)12-4-2-1-3-5-12/h1-11,24H,(H2,21,22,23,25)

Standard InChI Key:  INAQUFUHHQJFNF-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 25 28  0  0  0  0  0  0  0  0999 V2000
   -0.2731    2.0421    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.4414    2.4544    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.1533    2.0425    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.1533    1.2174    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.4432    0.8056    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.2731    1.2137    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0609    2.2982    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0610    0.9577    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.5479    1.6280    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.8706    0.8032    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.5880    1.2172    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.3028    0.8036    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.3028   -0.0248    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.5899   -0.4382    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.8706   -0.0285    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2754    0.1576    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.0754   -0.0566    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.2898   -0.8566    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.6611    0.5289    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -1.7042   -1.4426    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.9187   -2.2400    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.7190   -2.4544    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.3028   -1.8727    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.0932   -1.0720    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.5899   -1.2665    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  2  0
  3  2  1  0
  4  3  2  0
  5  4  1  0
  1  6  1  0
  6  5  2  0
  1  7  1  0
  6  8  1  0
  8  9  2  0
  9  7  1  0
 10  4  1  0
 11 10  2  0
 12 11  1  0
 13 12  2  0
 14 13  1  0
 10 15  1  0
 15 14  2  0
  8 16  1  0
 16 17  1  0
 17 18  1  0
 17 19  2  0
 20 18  2  0
 21 20  1  0
 22 21  2  0
 23 22  1  0
 24 23  2  0
 18 24  1  0
 14 25  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA5291397

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 330.35

Molecular Weight (Monoisotopic): 330.1117

AlogP: 3.58

#Rotatable Bonds: 3

Polar Surface Area: 90.90

Molecular Species: NEUTRAL

HBA: 4

HBD: 3

#RO5 Violations: ┄

HBA (Lipinski): 6

HBD (Lipinski): 3

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 9.01

CX Basic pKa: 4.86

CX LogP: 3.11

CX LogD: 3.10

Aromatic Rings: 4

Heavy Atoms: 25

QED Weighted: 0.54

Np Likeness Score: -0.97

References

1. Yang B, Zhang H, Li N, Gao L, Jiang H, Kan W, Yuan H, Li J, Zhao D, Xiong B, Zhou Y, Guo D, Liu T..  (2022)  Discovery of Novel N-(5-(Pyridin-3-yl)-1H-indazol-3-yl)benzamide Derivatives as Potent Cyclin-Dependent Kinase 7 Inhibitors for the Treatment of Autosomal Dominant Polycystic Kidney Disease.,  65  (23.0): [PMID:36384292] [10.1021/acs.jmedchem.2c01334]

Source

Source(1):

• Scientific Literature